Bill Chin, M.D. Dr. Bill Chin is the former chief medical officer of PhRMA and led the Scientific & Regulatory Advocacy department as executive vice president through the fall of 2017.
Recent Posts
The next five years of PDUFA VI: Driving the availability of innovative treatments for patients
By Bill Chin, M.D. | October 2, 2017
Yesterday, October 1, marked the first day of implementation for PDUFA VI, the next iteration of the Prescription Drug User Fee Act (PDUFA) and one of the best tools that the U.S. Food and Drug...
Read More
Mental health in the New Era of Medicine
By Bill Chin, M.D. | April 18, 2017
Research and development of innovative medicines to promote mental health are a priority for America’s biopharmaceutical research companies. With more than 130 medicines in development for mental...
Read More
Exploring the new era of medicine
By Bill Chin, M.D. | February 21, 2017
We are in a new era of medicine where innovations are transforming our ability to attack the cause of disease, not just the symptoms. Where treatment decisions are increasingly focused on the...
Read More
Reflecting on terrific progress in treating diabetes
By Bill Chin, M.D. | November 17, 2016
There is no doubt that diabetes is a complex disease to diagnose and treat. That’s something I’ve seen firsthand as an endocrinologist. Over the years, I treated a number of patients that had a...
Read More
What are REMS? These extra steps are helping protect patient health
By Bill Chin, M.D. | October 6, 2016
As a physician and chief medical officer at PhRMA, I know how important it is to ensure that patients have access to safe, innovative medicines to help them live longer, healthier lives. But...
Read More
Our continued commitment to combating Ebola
By Bill Chin, M.D. | October 15, 2015
Since March of 2014, there have been more than 28,000 cases of Ebola in West Africa, with more than 11,000 deaths, according to the World Health Organization (WHO). From the beginning of the...
Read More
The War on Alzheimer’s: Progress and Challenges of Biopharmaceutical Research
By Bill Chin, M.D. | July 15, 2015
Alzheimer’s disease steals memories, relationships and independence. It is a ruthless, devastating disease ravaging more than 5 million people in the United States alone, and is the sixth-leading...
Read More
Newly Implemented Expanded Access Principles Support Commitment to Patients
By Bill Chin, M.D. | June 3, 2015
Biopharmaceutical companies are committed to helping patients gain access to the best possible care, and its researchers are constantly looking for ways to provide more therapeutic options for...
Read More
Biopharmaceutical Sector Leads the Way in Clinical Trial Data Sharing
By Bill Chin, M.D. | March 15, 2015
Effective and responsible sharing of clinical trial data continues to expand scientific discourse and discovery, as we have chronicled here on the Catalyst. Through the PhRMA-EFPIA Principles for...
Read More
India—Seizing the Opportunity
By Bill Chin, M.D. | February 19, 2015
I am excited to be in India this week to discuss the scientific landscape of pharmaceutical research and development. Everywhere I go I see so much potential for India to become a leader in the...
Read More
Medicare Monday (100)
340B Spotlight (34)
Cost & Consequence (0)
